Zometa helpful for older breast cancer patients but not for younger ones

<![CDATA[

Novartis’s bone drug Zometa extended survival in older breast cancer patients but failed to improve disease-free survival among younger women patients in a large-scale clinical trial, researchers said on Sunday.

Detailed data presented at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm showed that Zometa, a bisphosphonate drug known generically as zoledronic acid, only improved overall survival rates in patients who had undergone the menopause at least five years earlier.

Researchers said the effect was likely to be linked to levels of reproductive hormones, which are lower in women who have been through the menopause.

Ref and Read more: https://www.fox2now.com/lifestyle/sns-rt-us-novartis-zometatre78o12n-20110925,0,5623503.story

]]>